Bayer's Nexavar gets priority review as thyroid cancer drug

FRANKFURT Tue Aug 27, 2013 10:52am EDT

A plant belonging to Germany's largest drugmaker Bayer is seen in Leverkusen January 30, 2013. REUTERS/Ina Fassbender

A plant belonging to Germany's largest drugmaker Bayer is seen in Leverkusen January 30, 2013.

Credit: Reuters/Ina Fassbender

Related Topics

Photo

Ebola epidemic

Quarantines and isolation units imposed to stop the spread of the worst Ebola outbreak in history.  Slideshow 

FRANKFURT (Reuters) - Bayer's cancer drug Nexavar was given priority review status by U.S. healthcare regulators for the oral drug's use against a difficult-to-treat type of thyroid cancer, the company said on Tuesday.

The U.S. Food and Drug Administration aims to complete the priority review within six months, rather than the standard review of about 10 months, Bayer said.

Bayer and development partner Onyx Pharmaceuticals are seeking a wider use for Nexavar to include treatment of patients with thyroid cancer that returned despite previous surgery and treatment with radioactive iodine, a group with a particularly poor prospect of survival.

Nexavar is already approved to treat liver as well as kidney cancer and it is also being tested on breast cancer patients.

(Reporting by Ludwig Burger)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.